Literature DB >> 8469466

Double-blind randomized study comparing amoxicillin and erythromycin for the treatment of Chlamydia trachomatis in pregnancy.

A H Magat1, L S Alger, D A Nagey, V Hatch, J C Lovchik.   

Abstract

OBJECTIVE: To compare the efficacy and patient tolerance of amoxicillin to that of erythromycin in the treatment of lower genital tract chlamydia infections during pregnancy.
METHODS: A double-blind, randomized study was conducted comparing oral amoxicillin 500 mg three times daily versus oral erythromycin 500 mg four times daily for 7 days. One hundred forty-three women with positive cervical cultures for chlamydia at less than 36 weeks' gestation were enrolled. A test-of-cure culture was obtained 4 weeks after entry into the study and side effects were assessed. Success of the regimen was defined as completing the course of medication and having a negative test-of-cure culture.
RESULTS: Thirty of the 65 women in the erythromycin group (46.1%) developed symptoms while taking the medication and 15 of them were unable to continue treatment (23.1%). In contrast, five of the 65 women (7.7%) in the amoxicillin group became symptomatic, with only one of these patients intolerant of the side effects (1.5%) (P < .001). Of the 50 patients in the erythromycin group who were able to complete their course of medication, only three had a positive test of cure (6.0%). In comparison, nine of the 64 patients (14.1%) taking amoxicillin who completed their course had positive cultures at test of cure. This difference was not statistically significant (P = .14). Forty-seven of the 65 patients (72.3%) in the erythromycin group successfully completed their regimen, compared to 55 of the 65 women (84.6%) in the amoxicillin group. This difference was not statistically significant.
CONCLUSIONS: These findings suggest that amoxicillin is a reasonable alternative for the treatment of chlamydia in pregnant patients intolerant to erythromycin. The incidence of side effects and intolerance to therapy for amoxicillin are less than those for erythromycin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8469466

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  14 in total

1.  Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Authors:  M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 2.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 3.  Drug therapies for sexually transmitted diseases. Clinical and economic considerations.

Authors:  W R Bowie
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

Review 4.  Interventions for treating genital chlamydia trachomatis infection in pregnancy.

Authors:  P Brocklehurst; G Rooney
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 5.  Chlamydia trachomatis in adolescents and adults. Clinical and economic implications.

Authors:  C A Marra; D M Patrick; R Reynolds; F Marra
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

6.  Treatment of Chlamydia trachomatis infections in pregnant women.

Authors:  J M Miller; D H Martin
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

7.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

8.  Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin.

Authors:  A S Beale; P A Upshon
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  The 1998 CDC Sexually Transmitted Diseases Treatment Guidelines.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.663

10.  A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy.

Authors:  J Kacmar; E Cheh; A Montagno; J F Peipert
Journal:  Infect Dis Obstet Gynecol       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.